Welcome to the UF Health Science Center Jacksonville Institutional Review Board site. This site is geared toward University of Florida faculty members, staff members and students who participate in research with human subjects.
Federal regulations require that all proposed research involving human subjects must be approved by an IRB prior to conducting research. According to the Federal regulations governing research, a "human subject" includes healthy volunteers, patients with specific diseases, medical records and pathological specimens. Our Federalwide Assurance number is FWA00005790.
All researchers and/or staff associated with human subjects research need to familiarize themselves with the Researcher Responsibilities. These responsibilities were previously outlined in our old Multiple Project Assurance (MPA) to the government. The responsibilities are now listed on our web site rather than the Assurance because (1) the MPA has expired and was recently replaced with a Federal Wide Assurance (FWA), and (2) the FWA does not specifically list researcher responsibilities.
The University of Florida IRB-03 reviews and approves human subjects research at the urban campus in Jacksonville, Fla. and the surrounding vicinity. Its usual schedule is to meet on the second and fourth Tuesdays of every month (except December). PIs are highly encouraged to attend meetings when their projects are being reviewed. Questions and concerns can be addressed quickly when PIs are present.
REQUIRED TRAINING FOR INVESTIGATORS!
NO APPROVALS WITHOUT PROOF OF COMPLETION
"HIPAA for Researchers" training is now available online. Click on the link, review the information and provide your certificate to the IRB office for safe-keeping. http://privacy.health.ufl.edu/training/Research08/online.shtml
Confused? Have questions about the IRB process or how HIPAA relates to human subject research? Call OR EMAIL the office! We are here to help you! 904-244-9427.
If this is your first experience with the Jacksonville IRB, please take a moment to read Getting Started for an overview of the process. Please feel free to call the IRB office at 244-9427 for assistance as well.
Click on a topic below for additional information:
- Forms and Instructions
- Guidance on Advertising for Subjects
- Information on Full Board Meetings
- IRB Updates
- HIPAA
- How Many Forms Need to be Submitted for Each Type of Submission
- Joint Projects with Gainesville
- Membership Roster for IRB-03
- 2006 Meeting Dates and Submission Deadline Dates
- 2007 Meeting Dates and Submission Deadline Dates
- Mission Statement
- NIH Tutorial
- Office and Contact Information
- Researcher Responsibilities
- Sample consent language for:
- Standardized text
- Coverage for Research-Related Costs
- Employees as Subjects
- Mammogram
- Magnetic Resonance Imaging (MRI)
- Placebo/Randomization
- Reproductive Risks
- Students as Subjects
- Venipuncture/Blood Draw Risk
- General Information on the Western Institutional Review Board (WIRB)
Please go to www.wirb.com to download the most current submission forms.
Notice:
The Institutional Biosafety Committee (IBC) must review all projects that involve HUMAN GENE THERAPY or Recombinant (rDNA) Therapy. A project that needs IBC review cannot begin until it has the approval of both the IBC and the IRB. Also, the IBC will review all revisions to human gene therapy projects to ensure that National Institutes of Health guidelines are being met. Therefore, investigators will be required to SUBMIT ALL REVISIONS TO BOTH the IBC and the IRB. THIS APPLIES TO LOCALLY REVIEWED STUDIES AND WIRB REVIEWED STUDIES. If you have questions about IBC review, please contact Dr. Phillip S. Collis at 392-1591 or via e-mail at pcollis@ehs.ufl.edu. Mail should be sent to Box 112190. Additional information can be obtained at: http://www.ehs.ufl.edu/Bio/default.asp.Use the WIRB IBC Cover Letter when submitting WIRB reviewed studies for IBC review.
WIRB - IBC Cover Letter
WIRB/UF Checklist
WIRB/UF Consent Template
Coming Soon:
- Investigator's Manual
- IRB-03 Policies and Procedures
Updated Thursday, March 29, 2007